🔗 Share this article

As the US undertakes unprecedented adjustments to its immunization schedules, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines during the pandemic and has zeroed in on possible fatalities after Covid vaccination in her short time at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders planned to announce radical changes to the childhood immunization program earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US out of step with much of the international standard with no evidence for improved outcomes. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this year.

A Shift at the Regulatory Body

The acting appointment might represent a strengthened alliance between the drug and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for halting some pediatric shot schedules in the US so as to align more like Denmark, a nation with universal health coverage and a citizenry approximately the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Background

The appointee has no obvious background in drug development, regulation or management, which has been typical for former leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since March.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the sort of resume that former directors who led CBER have had.”

CDER has an enormous workload at the agency, Woodcock stated.

“The public just pays attention on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and all of those must be looked after,” Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

There is also, a significant leadership element to the job, which manages over 5,000 staff members. “It’s a huge leadership role, if you do it right,” Woodcock added.

Official Statement and Controversial Initiatives

In response to concerns about Høeg’s fitness for the role and whether this appointment represents increased cooperation among FDA leaders on immunizations, a representative responded that the “concerns rely on incorrect premises”.

“Her resume is consistent with the duties of her role,” the representative said, noting the period Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial one-day drug-approval program that allegedly troubled her preceding directors. “How are these drugs being chosen for this fast-track system? Who takes the decisions?” Howard said. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards less stringent rules of most medications, except for vaccines.”

Public History on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if concerning, track record, some experts have noted. She released a study using unconfirmed public submissions to determine the frequency of heart inflammation following COVID-19 immunization. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the incoming federal leadership encompassed altering regulations for new vaccines and discontinuing “optional” vaccines, she said after the election on a audio program. At the agency, Høeg has allegedly suggested barring teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who starts off with her beliefs and reverse-engineers to fit the evidence in a extremely disingenuous, fraudulent way,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|